Trade GlaxoSmithKline PLC - GSKl CFD

GSK Company profile

GlaxoSmithKline PLC - GSK CFD

GlaxoSmithKline (GSK) is a global healthcare company focussed in pharmaceuticals, vaccine development and consumer healthcare products. 

The company began as an apothecary shop in London in 1715. Today, GlaxoSmithKline is headquartered in Brentford, England, with regional offices in the US and Singapore. GlaxoSmithKline’s primary listing is on the London Stock Exchange under the ticker symbol ‘GSK’. The GSK stock price in the form of  American depositary shares is listed on the New York Stock Exchange.   

GlaxoSmithKline’s pharmaceutical business covers a broad portfolio of medicines in respiratory, HIV, immuno-inflammation and oncology. The company has a leadership position in respiratory disease medicines. GlaxoSmithKline’s HIV business is managed through its unit ViiV Healthcare, with Pfizer and Shionogi as minority shareholders. 

In addition to respiratory and HIV treatments, the company has a portfolio of pharmaceutical products for the treatment of conditions such as lupus, urology and anti-infectives. 

Its Established Products Portfolio (EPP) includes mature medicines in the areas of anti-infectives, allergy, central nervous system, dermatology, respiratory and urology. These products are an important part of our Emerging Markets business.

GlaxoSmithKline is actively researching the World Health Organisation’s three priority diseases - HIV/AIDS, tuberculosis and malaria.

GlaxoSmithKline is also one of the world’s largest vaccine companies with a portfolio of more than 20 vaccines. The company has 12 vaccine manufacturing sites around the world. One of its four global R&D centres is dedicated to mRNA technology.

GlaxoSmithKline’s consumer healthcare business has portfolio of brands that include Sensodyne, Parodontax, Polident, Advil, Voltaire, Panadol, Striven, Theraflu and Centrum across oral health, pain relief, cold, flu and allergy, digestive health, and vitamins, mineral and supplements segments. GlaxoSmithKline is set to spin-off its consumer healthcare business into an independent company under the name ‘Haleon’.’

The company pays dividends on a quarterly basis, in July, October, January and April.
Follow the GlaxoSmithKline stock price live at Capital.com today.

Latest shares articles

ECB Preview: no doubt about a cut, but 25 and 50 are both valid.
The European Central Bank is expected to cut rates on Thursday, but 25 or 50 basis points remains debatable.
14:16, 10 December 2024
US CPI the final hurdle before December FOMC decision
US CPI data on December 11 will influence the Fed's December rate cut decision. Analysts predict a 2.7% CPI rise, with sticky inflation in services complicating the path to the 2% target. Market focus remains on core inflation and its impact on 2025 rate expectations.
08:37, 10 December 2024
Market Analysis: stocks unbothered by politics ahead of US CPI
Global stocks remain at all-time highs despite several political events as investors focus on the US CPI data.
17:56, 9 December 2024
The RBA expected to keep policy unchanged at its December meeting
The RBA is set to meet for the final time in 2024, with the central bank handing down its decision at 2:30PM on Tuesday the 10th of December.
10:43, 6 December 2024

Read our reviews to find out more about us

Read the feedback from our clients around the world.
2024-10-22
infoaamon

Very trustworthy and affordable for any size trades

2024-10-21
remi74

It is very easy to connect with TradingView but the web interface is also great.

2024-10-15
jdancer37

Easy to use and great support. Been using it for 2 years already and still happy

2024-10-14
DANIEL

Capital.com is one of the best stock trading platforms I’ve used. The UX and UI on both the mobile app and web platform are outstanding, making it incredibly easy to navigate. They’ve built a vibrant community of traders and investors, and their UAE team really stands out for delivering an exceptional trading experience.

2024-10-08
Yahyaamez

Best broker!! they call you to see if you need any help. The app is good and nice better than the rest

2024-10-04
Iuliia Salivon

Great app! I requested some features to be added, such as analysis tools, and they delivered. Amazing job! The agents are always helpful and reply quickly. It’s not 5 stars because, at times, some less experienced agents may say it’s impossible to fulfill the request or fix the problem while another agent, like Angel, quickly escalated the issue to the necessary team/person/department and resolved it

2024-10-04
Moh ST

This is an excellent platform. The stop loss and take profit work very well; however, when the changes are very fast like at the beginning of the session, the stop loss does not work. If this defect is corrected it will be the perfect platform.

2024-09-30
adenysenko24

-Nice -Easy to use - Beautiful Interface

2024-09-26
Daniel

I think I'm new in this trading platform, but I find it affordable and most reliable. To be honest I'm not fully experienced trader, but with very limited knowledge of trading I try learn as much as I can by trying out different platforms see if can make money. My interests growing in you platform, l like news updates you also short videos on YouTube, other propaganda, poster and many more. I will see what happens in the coming months. Thanks capital team.

2024-09-26
John Fallows

Gives you options to start learning how too do it as it gives you a demo option to learn from your mistakes

2024-09-24
PHEMELO

Efficiency. When creating the account, it was smooth, efficient from start to finish. Verification of documents also was done the same day, unlike other platforms where you have to wait a day or two.

2024-09-04
Osondu Paul

From what I'm seeing it's cool Mixing it with trading view it's perfect... I didn't give it 5 star yet cos I still need to use it for some time

Showing our 4 & 5 star reviews

Ready to join a leading broker?

Join our community of traders worldwide
1. Create your account2. Make your first deposit3. Start trading